HELIX BIOPHARMA CORP (HBP.CA) Stock Price, Forecast & Analysis
TSX:HBP • CA4229102088
HBP.CA Key Statistics, Chart & Performance
The current stock price of HBP.CA is 1.85 CAD. In the past month the price decreased by -14.75%. In the past year, price increased by 90.72%.
HBP.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to HBP.CA. When comparing the yearly performance of all stocks, HBP.CA is one of the better performing stocks in the market, outperforming 72.75% of all stocks.
HBP.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HBP.CA. Both the profitability and financial health of HBP.CA have multiple concerns.
HBP.CA Financial Highlights
Over the last trailing twelve months HBP.CA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 56.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.58% | ||
| ROE | -30.36% | ||
| Debt/Equity | 0.02 |
HBP.CA Forecast & Estimates
HBP.CA Ownership
HBP.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 596.271M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 380.328M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 69.23M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 44.744M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.875M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.45 | 30.481M | ||
| RVX | RESVERLOGIX CORP | N/A | 27.318M | ||
| HEM | HEMOSTEMIX INC | N/A | 17.573M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About HBP.CA
Company Profile
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The firm is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
Company Info
HELIX BIOPHARMA CORP
Bay Adelaide Centre - North Tower 40, Temperance Street, Suite 2700 Toronto
TORONTO ONTARIO L4B 3J9 CA
CEO: Heman Chao
Employees: 7
Phone: 16046842181
HELIX BIOPHARMA CORP / HBP.CA FAQ
What does HELIX BIOPHARMA CORP do?
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The firm is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
What is the current price of HBP stock?
The current stock price of HBP.CA is 1.85 CAD. The price increased by 0.54% in the last trading session.
Does HBP stock pay dividends?
HBP.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of HBP stock?
HBP.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of HELIX BIOPHARMA CORP (HBP.CA)?
HELIX BIOPHARMA CORP (HBP.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
Would investing in HELIX BIOPHARMA CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HBP.CA.
When does HELIX BIOPHARMA CORP (HBP.CA) report earnings?
HELIX BIOPHARMA CORP (HBP.CA) will report earnings on 2026-03-12.